Health Care [ 2/12 ] | Biotechnology [ 21/74 ]
NASDAQ | Common Stock
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States.
Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials.
The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene and its secreted gene product, Activin E in Phase 1/2a clinical trials; ARO-ALK7 to silence adipocyte expression of the ACVR1C gene in Phase 1/2a clinical trials; ARO-RAGE to reduce production of the receptor for advanced glycation end products in Phase 1/2a clinical trials; and ARO-MAPT, an investigational RNAi-based therapy.
In addition, it is developing ARO-C3 to reduce production of C3 in Phase 1/2a clinical trials; and ARO-CFB to reduce hepatic expression of CFB in a Phase 1/2a clinical trials.
The company has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Takeda Pharmaceutical Company Limited; Amgen Inc.; and Sarepta Therapeutics, Inc. Arrowhead Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Pasadena, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 3, 26 | -1.36 Decreased by -7.94% | -1.23 Decreased by -10.57% |
| May 6, 26 | -0.93 Decreased by -133.82% | -1.11 Increased by +16.22% |
| Feb 4, 26 | 0.22 Increased by +115.83% | -0.37 Increased by +159.46% |
| Nov 24, 25 | -0.11 Increased by +91.97% | -0.31 Increased by +64.50% |
| Aug 6, 25 | -1.26 Increased by +8.70% | -0.94 Decreased by -34.04% |
| May 11, 25 | 2.75 Increased by +369.61% | -0.46 Increased by +697.83% |
| Feb 9, 25 | -1.39 Decreased by -12.10% | -0.72 Decreased by -93.06% |
| Nov 26, 24 | -1.37 Decreased by -34.31% | -0.92 Decreased by -48.59% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 29, 26 | 75.25 M Increased by +171.02% | -194.28 M Decreased by -10.86% | Decreased by -258.17% Increased by +59.09% |
| Mar 30, 26 | 73.74 M Decreased by -86.41% | -132.73 M Decreased by -135.83% | Decreased by -180.01% Decreased by -363.71% |
| Dec 30, 25 | 264.03 M Increased by +10.46 K% | 30.81 M Increased by +117.80% | Increased by +11.67% Increased by +100.17% |
| Sep 29, 25 | 256.47 M Increased by +987.25% | -23.75 M Increased by +86.07% | Decreased by -9.26% Increased by +98.72% |
| Jun 29, 25 | 27.77 M Increased by +N/A% | -175.24 M Decreased by -2.60% | Decreased by -631.11% Decreased by N/A% |
| Mar 30, 25 | 542.71 M Increased by +N/A% | 370.44 M Increased by +395.65% | Increased by +68.26% Decreased by N/A% |
| Dec 30, 24 | 2.50 M Decreased by -29.60% | -173.09 M Decreased by -30.27% | Decreased by -6.92 K% Decreased by -85.04% |
| Sep 29, 24 | 23.59 M Increased by +46.54% | -170.54 M Decreased by -55.49% | Decreased by -722.95% Decreased by -6.10% |